Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755235 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4308762 | 0.84 | CHRM2 (0.38) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4301629 | 0.84 | CHRM2 (0.38) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL16349058 | 0.81 | HSD17B10 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4311042 | 0.81 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4308133 | 0.81 | HSD17B10 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL13689098 | 0.81 | HSD17B10 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4304713 | 0.81 | NR1H2 (0.34) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL14451045 | 0.81 | HSD17B10 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL8353738 | 0.81 | HSD17B10 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096277-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096277-A1 | PROCESSES AND INTERMEDIATES | CYP1B1, CYP3A7, CYP7A1 | NR1H2 449/4885CHRM2 3019/4885CHRM1 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.